CRYSTALLINE FORMS OF AN INHIBITOR OF THE MENIN/MLL INTERACTION

Title:

CRYSTALLINE FORMS OF AN INHIBITOR OF THE MENIN/MLL INTERACTION

Document Type and Number:

WIPO Patent Application WO/2023/193790

Kind Code:

A1

Abstract:

The present invention relates to crystalline forms of an inhibitor of menin/mixed lineage leukemia (MLL) protein-protein interaction. The present invention also relates to pharmaceutical compositions comprising crystalline forms of an inhibitor of menin/mixed lineage leukemia (MLL) protein-protein interaction. These crystalline forms and pharmaceutical compositions comprising said crystalline forms may be useful for treating diseases such as cancer.

More Like This:

JP2011516094	The siren シング method of CSN5 gene expression using interference RNA
JP2017160210	TREATMENT WITH ANTI-ERBB2 ANTIBODY
JP5313886	Antibodies that recognize carbohydrate-containing epitopes of CD-43 and CEA expressed in cancer cells and methods of using them

Inventors:

CAI WEI (CN)
THURING JOHANNES WILHELMUS J (BE)
HULPIA FABIAN (BE)
DAI XUEDONG (CN)
LI MING (CN)
NG ALICIA TEE FUAY (CN)
DARVILLE NICOLAS FREDDY JACQUES BRUNO (BE)
PANDE VINEET (BE)

Application Number:

PCT/CN2023/086884

Publication Date:

October 12, 2023

Filing Date:

April 07, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

JANSSEN PHARMACEUTICA NV (BE)
JOHNSON & JOHNSON CHINA INVEST LTD (CN)

International Classes:

A61P35/00; C07D471/04

Domestic Patent References:

WO2018053267A1	2018-03-22
WO2014199171A1	2014-12-18
WO2011113798A2	2011-09-22
WO2013037411A1	2013-03-21
WO2011056440A1	2011-05-12
WO2021060453A1	2021-04-01
WO2022253167A1	2022-12-08
WO2022253167A1	2022-12-08

Attorney, Agent or Firm:

NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD. (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: WEE1 DEGRADING COMPOUNDS

Next Patent: COMMUNICATION METHOD AND COMMUNICATION APPARATUS